How would China achieve WHO’s target of eliminating HCV by 2030?

References

• Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet. 2016 Sep 10;388(10049):1081–1088.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen LM, He M. Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution. Virol J. 2017 Feb 23;14(1):41.
   PubMedGoogle Scholar
• Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014 Nov;61(1 Suppl):S58–68.
   PubMedGoogle Scholar
• Bian DD, Zhou HY, Liu S, et al. Current treatment status and barriers for patients with chronic HCV infection in mainland China: A national multicenter cross-sectional survey in 56 hospitals. Medicine (Baltimore). 2017 Aug;96(34):e7885.
   PubMed Web of Science ®Google Scholar
• Global Hepatitis Report 2017. Geneva: World Health Organization. 2017. Licence: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• World Health Organisation Westen Pacific Region Office. The number of chronic hepatitis deaths in China can be as high as 10 million by 2030: urgent action is required to end the “silent epidemic”. 2016.
   Google Scholar
• Polaris Observatory. Hep C- Dashboard, 2018. 2004–2016. [cited 2019 Sep 30]. Available from: http://cdafound.org/polaris-hepC-dashboard/
   Google Scholar
• Polaris Observatory, H. C. V. Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet. 2017 Mar;2(3):161–176.
   PubMed Web of Science ®Google Scholar
• Revill PA, Chisari FV, Block JM, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4(7):545–558.
   PubMed Web of Science ®Google Scholar
• Zhuang H. Report on the Status of Hepatitis C Infection in China and Prevention and Treatment Strategies. China: People’s Medical Publishing House; 2017.
   Google Scholar
• Chen F, Sun D, Guo Y, et al. Correction: spatiotemporal scan and age-period-cohort analysis of hepatitis C Virus in Henan, China: 2005–2012. PLoS One. 2015;10(8):e0136333.
   PubMed Web of Science ®Google Scholar
• Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 2013 Aug;28(Suppl 1):7–10.
   PubMed Web of Science ®Google Scholar
• Kang L, Sun Y, Hao L, et al. Studies on epidemiology of the population with HCV and HEV infections and their epidemic factors in China. Chin J Infect Dis. 1997;15:7175.
   Google Scholar
• Gao X, Cui Q, Shi X, et al. Prevalence and trend of hepatitis C virus infection among blood donors in Chinese mainland: a systematic review and meta-analysis. BMC Infect Dis. 2011 Apr;9(11):88.
   Google Scholar
• Midgard H, Weir A, Palmateer N, et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol. 2016 Oct;65(Suppl 1):S33–S45.
   PubMedGoogle Scholar
• Xia X, Luo J, Bai J, et al. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health. 2008 Oct;122(10):990–1003.
   PubMed Web of Science ®Google Scholar
• Li ZB, Zhang L, Wang J, et al. Hepatitis C infection, related services, and barriers to HCV treatment among drug users in methadone maintenance treatment (MMT) clinics in Shanghai, China. Harm Reduct J. 2017 Nov 2;14(1):71.
   PubMedGoogle Scholar
• Zhou YH, Yao ZH, Liu FL, et al. High prevalence of HIV, HCV, HBV and co-infection and associated risk factors among injecting drug users in Yunnan province, China. PLoS One. 2012;7(8):e42937.
   PubMed Web of Science ®Google Scholar
• Sun J, Yu R, Zhu B, et al. Hepatitis C infection and related factors in hemodialysis patients in china: systematic review and meta-analysis. Ren Fail. 2009;31(7):610–620.
   PubMed Web of Science ®Google Scholar
• Xie J, Han Y, Qiu Z, et al. Prevalence of hepatitis B and C viruses in HIV-positive patients in China: a cross-sectional study. J Int AIDS Soc. 2016;19(1):20659.
   PubMedGoogle Scholar
• Zhang F, Zhu H, Wu Y, et al. HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010–12: a retrospective observational cohort study. Lancet Infect Dis. 2014 Nov;14(11):1065–1072.
   PubMed Web of Science ®Google Scholar
• Wu SZ, Wei JL, Xu B, et al. Detection and analysis of hepatitis C virus in HIV-infected patients in the Guangxi province of China. Exp Ther Med. 2017 Mar;13(3):917–923.
   PubMed Web of Science ®Google Scholar
• Duan Z, Jia JD, Hou J, et al. Current challenges and the management of chronic hepatitis C in mainland China. J Clin Gastroenterol. 2014 Sep;48(8):679–686.
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hepatology. Chinese Medical Association, Wei L, Chinese society of infectious diseases, Chinese medical association, Hou JL. The guideline of prevention and treatment for hepatitis C: a 2015 update. Zhonghua Gan Zang Bing Za Zhi. 2015 Dec;23(12):906–923.
   PubMedGoogle Scholar
• Chen Y, Yu C, Yin X, et al. Hepatitis C virus genotypes and subtypes circulating in Mainland China. Emerg Microbes Infect. 2017 Nov 1;6(11):e95.
   PubMedGoogle Scholar
• Rong X, Xu R, Xiong H, et al. Increased prevalence of hepatitis C virus subtype 6a in China: a comparison between 2004–2007 and 2008–2011. Arch Virol. 2014 Dec;159(12):3231–3237.
   PubMed Web of Science ®Google Scholar
• Wu Z, Cui L, Zhao W, et al. Molecular epidemiology of hepatitis C infections in Ningxia, China: genotype, phylogeny and mutation analysis. Virol J. 2016 Oct 18;13(1):172.
   PubMedGoogle Scholar
• Fu Y, Wang Y, Xia W, et al. New trends of HCV infection in China revealed by genetic analysis of viral sequences determined from first-time volunteer blood donors. J Viral Hepat. 2011 Jan;18(1):42–52.
   PubMed Web of Science ®Google Scholar
• Chen W, Liao B, Hu F, et al. Changing epidemiology of hepatitis c virus genotype among patients with human immunodeficiency Virus/Hepatitis C Virus Co-Infection in China. PLoS One. 2016;11(9):e0161844.
   PubMed Web of Science ®Google Scholar
• Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3(2):47–52.
   PubMedGoogle Scholar
• Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol. 2014 Aug 28;20(32):11033–11053.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Tanaka A, Eguchi Y, et al. The impact of hepatitis C virus outside the liver: evidence from Asia. Liver Int. 2017 Feb;37(2):159–172.
   PubMed Web of Science ®Google Scholar
• Bennett H, Waser N, Johnston K, et al. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. Hepatol Int. 2015 Jul;9(3):378–390.
   PubMed Web of Science ®Google Scholar
• van der Meer AJ. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015 Mar;64(3):364–366.
   PubMed Web of Science ®Google Scholar
• Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012 Aug 15;206(4):469–477.
   PubMed Web of Science ®Google Scholar
• Matsushita H, Ikeda F, Iwasaki Y, et al. Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C. J Gastroenterol Hepatol. 2014 Feb;29(2):337–343.
   PubMed Web of Science ®Google Scholar
• Sobhonslidsuk A, Silpakit C, Kongsakon R, et al. Factors influencing health-related quality of life in chronic liver disease. World J Gastroenterol. 2006 Dec 28;12(48):7786–7791.
   PubMed Web of Science ®Google Scholar
• Huang R, Rao H, Shang J, et al. A cross-sectional assessment of health-related quality of life in Chinese patients with chronic hepatitis c virus infection with EQ-5D. Health Qual Life Outcomes. 2018 Jun 15;16(1):124.
   PubMedGoogle Scholar
• Zhang HR, Pan GW, Xu XG, et al. Study on quality of life and its related factors among patients with chronic hepatitis C in rural area. Zhonghua Yu Fang Yi Xue Za Zhi. 2017 Sep 6;51(9):853–855.
   PubMedGoogle Scholar
• Jia Y, Li X, Li L, et al. Quality of life and its influential factors in outpatients with chronic hepatitis B or C. J Clin Hepatol (Lin Chuang Gan Dan Bing Za Zhi). 2015 Sep;31(10):1695–1698.
   Google Scholar
• Sun YT, Zhang YX, Tang H, et al. Clinical characteristics and current management of hepatitis B and C in China. World J Gastroenterol. 2014 Oct 7;20(37):13582–13590.
   PubMed Web of Science ®Google Scholar
• Suwanthawornkul T, Anothaisintawee T, Sobhonslidsuk A, et al. Efficacy of second generation direct-acting antiviral agents for treatment naive hepatitis C Genotype 1: a systematic review and network meta-analysis. PLoS One. 2015;10(12):e0145953.
   PubMed Web of Science ®Google Scholar
• World Hepatitis Alliance. HCV quest - global patient survey. contry-specific report China 2016. [ Cited 2018 5 October]. Available from: http://www.worldhepatitisalliance.org/hcv-quest-global-patient-survey-china-en-report
   Google Scholar
• Beijing Business Today. Non-invasive diagnostics FibroScan PRO now approved. 2019 [updated Mar 19, 2019; [cited 2019 Sep 27]. Available from: https://finance.sina.com.cn/roll/2019-03-19/doc-ihrfqzkc4969532.shtml
   Google Scholar
• Feng B, Zhang J, Wei L. Inadequate awareness of hepatitis C among nonspecialist physicians in China. Adv Med Educ Pract. 2011 10 Oct;2:209–214.
   PubMedGoogle Scholar
• Daw MA, El-Bouzedi AA, Ahmed MO, et al. Geographic integration of hepatitis C virus: A global threat. World J Virol. 2016 Nov 12;5(4):170–182.
   PubMedGoogle Scholar
• Enterprise Singapore. About Belt and Road Initiative. [cited 2019 Apr 10]. Available at: https://ie.enterprisesg.gov.sg/Venture-Overseas/Browse-By-Market/Asia-Pacific/China/About-OBOR
   Google Scholar
• Chaabna K, Cheema S, Abraham A, et al. Systematic overview of hepatitis C infection in the Middle East and North Africa. World J Gastroenterol. 2018 Jul 21;24(27):3038–3054.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization 2018. Licence: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• European Association for the Study of the Liver. EASL recommendations on treatment of Hepatitis C 2018. J Hepatol. 2018 Aug;69(2):461–511.
   PubMed Web of Science ®Google Scholar
• Kirby institute. Monitoring hepatitis C treatment uptake in Australia - Issue 9. [cited 2019 Apr 10]. Available at: https://kirby.unsw.edu.au/sites/default/files/kirby/report/Monitoring-hep-C-treatment-uptake-in-Australia_Iss9-JUL18.pdf
   Google Scholar
• Kattakuzhy S, Gross C, Emmanuel B, et al. Expansion of treatment for Hepatitis C Virus Infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial. Ann Intern Med. 2017 Sep 5;167(5):311–318.
   PubMed Web of Science ®Google Scholar
• Chan HLY, Lai C-L, Feld J, et al. Sofosbuvir/velpatasvir for 12 weeks results in high SVR12 rates with a favorable safety profile in Asian patients from ASTRAL-1/2/3. Singapore Hepatology Conference; 2–3 June; Singapore; 2017. p. 28–29.
   Google Scholar
• Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial. J Hepatol. 2016 Jul;65(1):33–39.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir and velpatasvir combination improves patient-reported outcomes for patients with HCV Infection, without or with compensated or decompensated cirrhosis. Clin Gastroenterol Hepatol. 2017 Mar;15(3):421–30 e6.
   PubMed Web of Science ®Google Scholar
• Lee R, Kottilil S, Wilson E. Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy. Hepatol Int. 2017 Mar;11(2):161–170.
   PubMed Web of Science ®Google Scholar
• Puoti M, Foster GR, Wang S, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1–6 patients without cirrhosis. J Hepatol. 2018 Aug;69(2):293–300.
   PubMed Web of Science ®Google Scholar
• Aghemo A, Bourgeois S, Gschwantler M, et al., editors. Real-world health care resource utilization and quality of life with glecaprevir/pibrentasvir treatment: a pooled analysis from post-marketing observational studies. 2019 AASLD/EASL HCV Special Conference 01–02; 2019; Miami, FL.
   Google Scholar
• Feld J, Gonzalez YS, Santos APD, et al., editors. Clinical benefits, economic savings and faster time to HCV Elimination with a simplified 8-week treatment and monitoring program in chronic F0-F3 naïve patients in the US. The Liver Meeting; 2018; San Francisco.
   Google Scholar
• Lazarus JV, Safreed-Harmon K, Thursz MR, et al. The micro-elimination approach to eliminating Hepatitis C: strategic and operational considerations. Semin Liver Dis. 2018 Aug;38(3):181–192.
   PubMed Web of Science ®Google Scholar
• Lazarus JV, Wiktor S, Colombo M, et al. Micro-elimination - A path to global elimination of hepatitis C. J Hepatol. 2017 Oct;67(4):665–666.
   PubMed Web of Science ®Google Scholar
• Alimohammadi A, Holeksa J, Bassi A, et al. Recurrent viremia after successful hepatitis C virus therapy with direct-acting antivirals in a cohort of people who use drugs. J Hepatol. 2018;68(Suppl 1):S544.
   Google Scholar
• Read P, Lothian R, Chronister K, et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy. 2017 Sep;47:209–215.
   PubMed Web of Science ®Google Scholar
• Zhou L, Zeng XX, Fu P. Community hemodialysis in China: opportunities and challenges. Chin Med J (Engl). 2017 Sep 20;130(18):2143–2146.
   PubMed Web of Science ®Google Scholar
• Huang H, Ding Y, Wang H, et al. The ethical sensitivity of health care professionals who care for patients living with hiv infection in hunan, china: a qualitative study. J Assoc Nurses AIDS Care. 2018 Mar - Apr;29(2):266–274.
   PubMed Web of Science ®Google Scholar
• National Centre for STD Control, China CDC. Overview of HIV Management in China. Assessed 26September 2018.
   Google Scholar
• Lin W, Chen S, Seguy N, et al. Is the HIV sentinel surveillance system adequate in China? Findings from an evaluation of the national HIV sentinel surveillance system. Western Pac Surveill Response J. 2012 Oct;3(4):76–85.
   PubMedGoogle Scholar
• Zhang L, Chow EP, Zhang J, et al. Describing the Chinese HIV surveillance system and the influences of political structures and social stigma. Open AIDS J. 2012;6:163–168.
   PubMedGoogle Scholar
• Braun DL, Hampel BH, Nguyen H, et al. A treatment as prevention trial to eliminate HCV in HIV positive men who have sex with men: the Swiss HCVree Trial - e-health assisted behavioral intervention to reduce risk in HCV re-infection in MSM. Abstract presented at: O-06. Conference on Retroviruses and Opportunistic Infections (CROI); Boston, Massachusetts, The United States; 2018.
   Google Scholar
• Boerekamps A, van Den Berk GE, Lauw FN, et al. Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive men who have sex with men after unrestricted access to HCV therapy. Clin Infect Dis. 2018 Apr 17;66(9):1360–1365.
   PubMed Web of Science ®Google Scholar
• Song X, Du H, Yang L, et al. HCV infection status and epidemiological characteristics of 68125 females of child-bearing age. Zhongguo Wei Sheng Jian Yan Za Zhi. 2014;24(16):2377–2379.
   Google Scholar
• Li J, Yang W, Wang Z. Epidemiological characteristics of HCV infected children under 15 years of age, in Henan province from 2008 to 2013. Zhonghua Liu Xing Bing Xue Za Zhi. 2014 Oct;35(10):1119–1122.
   PubMedGoogle Scholar
• Mok J, Pembrey L, Tovo PA, et al. When does mother to child transmission of hepatitis C virus occur? Arch Dis Child Fetal Neonatal Ed. 2005 Mar;90(2):F156–60.
   PubMed Web of Science ®Google Scholar
• Benova L, Mohamoud YA, Calvert C, et al. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis. 2014 Sep 15;59(6):765–773.
   PubMed Web of Science ®Google Scholar
• Nwaohiri A, Schillie S, Bulterys M, et al. Hepatitis C virus infection in children: how do we prevent it and how do we treat it? Expert Rev Anti Infect Ther. 2018 Sep;16(9):689–694.
   PubMed Web of Science ®Google Scholar
• China’s Viral Hepatitis Prevention and Control Plan 2017–2020. [cited 2019 Apr 10]. Available from: http://www.bjhlxh.com/about/988.html
   Google Scholar
• Moon S, Erickson E. Universal Medicine Access Through Lump-Sum Remuneration - Australia’s approach to Hepatitis C. N Engl J Med. 2019 Feb 14;380(7):607–610.
   PubMed Web of Science ®Google Scholar
• Li H, Liu GG, Wu J, et al. Recent pricing negotiations on innovative medicines pilot in China: experiences, Implications, and Suggestions. Value Health Reg Issues. 2018;15:133–137.
   PubMedGoogle Scholar
• Gilead Sciences. Provincial-level Reimbursement Decisions. Unpublished data on file.
   Google Scholar
• Yuan Y. New concepts in HCV treatment. 2008 [cited 2019 Jul]. Available from: http://www.lifeweek.com.cn/2008/1224/23433.shtml
   Google Scholar
• Palumbo E. Pegylated interferon and ribavirin treatment for hepatitis C virus infection. Ther Adv Chronic Dis. 2011 Jan;2(1):39–45.
   PubMedGoogle Scholar
• Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015 Dec 31;373(27):2599–2607.
   PubMed Web of Science ®Google Scholar
• Kaishima T, Akita T, Ohisa M, et al. Cost-effectiveness analyses of anti-hepatitis C virus treatments using quality of life scoring among patients with chronic liver disease in Hiroshima prefecture, Japan. Hepatol Res. 2018 Jun;48(7):509–520.
   PubMed Web of Science ®Google Scholar
• Stahmeyer JT, Rossol S, Liersch S, et al. Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany. PLoS One. 2017;12(1):e0169401.
   PubMed Web of Science ®Google Scholar
• Wisloff T, White R, Dalgard O, et al. Economic evaluation of direct-acting antivirals for hepatitis C in Norway. Pharmacoeconomics. 2018 May;36(5):591–601.
   PubMed Web of Science ®Google Scholar
• Chhatwal J, He T, Hur C, et al. Direct-acting antiviral agents for patients with Hepatitis C Virus Genotype 1 infection are cost-saving. Clin Gastroenterol Hepatol. 2017 Jun;15(6):827–37 e8.
   PubMed Web of Science ®Google Scholar
• Xie Q, Xuan JW, Tang H, et al. Hepatitis C virus cure with direct acting antivirals: clinical, economic, societal and patient value for China. World J Hepatol. 2019 May 27;11(5):421–441.
   PubMed Web of Science ®Google Scholar
• Backus LI, Belperio PS, Shahoumian TA, et al. Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease. Hepatology. 2018 Sep;68(3):827–838.
   PubMed Web of Science ®Google Scholar
• Mangia A, Lawitz E, Gane E, et al. Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens. J Hepatol. 2018;68(Suppl 1):S67–S8.
   Google Scholar
• Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017 Sep 5;S0168–8278(17):32273.
   Google Scholar
• Tang H, Wu J, Wu B, et al. Long-term outcomes associated with sofosbuvir/velpatasvir for treatment of chronic hepatitis C in China. International Society for Pharmacoeconomics and Outcomes Research conference (ISPOR). Tokyo, Japan; 2018.
   Google Scholar
• Dayoo. Efforts towards hepatitis elimination in 2030, those in low-income household can now apply for free drugs. 2018 [cited 2019 Jul]. Available from: http://news.sina.com.cn/c/2018-07-26/doc-ihfvkitx0242256.shtml
   Google Scholar